

ASX:MVP

Medical Developments International

November 2023



Penthrox Inhaler

CRIPTION ONLY methoxyflu the second secon

Spac

Cham



IMPORTANT INFORMATION

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

- 1. pricing and product initiatives of competitors;
- legislative and regulatory developments and economic conditions;
- delay or inability in obtaining regulatory approvals or bringing products to market;
- 4. fluctuations in currency exchange rates and general financial market conditions;
- products;
- 6. increased government pricing pressures;
- 7. interruptions in production;
- 8. loss or inability to obtain adequate protection for intellectual property rights;
- 9. litigation;
- 10. loss of key executives or other employees; and
- 11. adverse publicity and news coverage.

There can be no assurance that any existing or future regulatory filings will satisfy any health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Medical Development International Limited is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Any statements regarding earnings is not a profit forecast and should not be interpreted to mean that Medical Developments International's earnings for this year or any subsequent period will necessarily match or exceed the historical published earnings of Medical Developments International. Medical Developments International Limited, its directors, officers and employees do not accept any liability whatsoever for any damage or loss caused by anything contained in this document.

For marketed products discussed in this presentation, please see full prescribing information on our website at www.medicaldev.com All mentioned trademarks are legally protected.


Non-IFRS Financial Information

This presentation uses non-IFRS financial information including underlying revenue, EBIT and free cashflow. These measures are key performance measures used by the Company, the investment community, and peers with similar business. portfolios. The Company uses these measures for its internal management reporting as it better reflects what the Company considers to be its underlying performance. Underlying revenue and EBIT are used to measure segment performance and have been extracted from the segment information disclosed in the Full Year Consolidated Financial Report.



5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed





Company overview

Medical Developments International ("MDI") is a leading Australian pain management medical technologies company whose key product Penthrox® has been approved in 40 countries globally

MDI is an ASX¹ listed medical technology company that specializes in pain management, emergency medical solutions and respiratory products

Key product is **Penthrox**, a non-opioid analgesic used for pain relief by self-administration patients with trauma and those requiring analgesia for minor surgical procedures

We have a portfolio of respiratory products for sufferers of asthma and COPD

Snapshot

ASX¹: MVP (market capitalisation ~\$70 million)

Financials

- Revenue \$32.4 million in FY23
- Cash balance \$25 million at 30 June 2023
- NPAT in FY23 of \$5.6 million (loss)


Board and Management

- Chair: Gordon Naylor
- Non-executive Directors: Mary Sontrop, Richard Betts, Christine Emmanuel-Donnelly, Russell Basser, Leon Hoare
- CEO: Brent MacGregor
- CFO: Anita James





The assessment and treatment of pain in the emergency department (ED) is often inadequate





Crowded emergency rooms have increasingly led patients to on-demand sites of care (e.g., urgent care), necessitating the use of analgesics which are easy to use



The **role of paramedics is expanding from transporters in the patient care journey to care providers**, driving EMS demand for non-opioid pain management alternatives

Overcrowding and slowed patient throughput has increased hospital emphasis on driving workflow efficiency

The opioid epidemic has led to a **growing shift in prescriber preferences away from opioids**, which has created opportunities for newer, innovative products to gain a foothold in the market





Penthrox Over 9 million used worldwide

- Inhaled needle-free analgesic¹
- Non-opioid¹
- Portable, self administered device¹
- Pain relief which should start after 6-10 breaths¹⁻⁴
- Established safety profile with over 9 million uses
- Adverse events include headache and dizziness; the majority of adverse events mild and transient^{1,2}
- Approved for use in children in Australia¹
- Efficiency of Penthrox in hospital emergency departments illustrated in British study⁵

- 2. Coffey F, et al. Emerg Med J 2014;31:613-618.
- 3. Grindlay J, Babl FE. Emerg Med Australasia 2009;21:4-11.
- 4. Penthrox[®] (methoxyflurane) Consumer Medicine Information October 2023
- Craigavon, N.I., An inhaled analgesic 31 March 2020 5.





The iconic Green Whistle







^{1.} Penthrox[®] (methoxyflurane) Approved Product Information October 2023.

Hospital throughput and efficiency study (Young et al, 2020)

Study overview

- Study design: A prospective, observational cohort-defined service evaluation, conducted over 6 months in the ED of St Mary's Hospital, London
- Objective: assess efficacy, costs of providing analgesia, impact on pain and service impact of methoxyflurane compared with standard of care (mainly consisting of IV opioids or procedural sedation)
- Patient population: Adult patients with moderate to severe trauma pain

Key Results

Length-of-stay for all injuries and shoulder dislocations


276mins with Penthrox **347**mins with SoC treatment

The use of Penthrox significantly reduced overall ED patient length of stay vs. standard care* by 71 min [276 min (range 30–967 min) vs. 347 min (range 94–1382 min) (p = 0.038)], with a more pronounced reduction of 183 min (p=0.09) in patients presenting with shoulder dislocation.



Treatment administered for all injuries

Treatment administered for shoulder dislocations








Penthrox is registered in over 40 countries

Partner	Territories		
MDI Direct Sales	Australia, France, Switzerland, Belgium		
Daiichi Sankyo	Thailand		
Douglas	New Zealand		
Equity	South Africa, Namibia, Botswana, Zambia		
Galen	UK, Finland, Sweden, Norway, Denmark, Iceland		
Link	Hong Kong, Singapore		
Mactuary	Taiwan		
Medis	Austria, Czech Republic, Slovakia, Slovenia, Hungary, Croatia		
Paladin	Canada		
Stendhal	Mexico		
UAE	Pharma Solutions		
UITC	Qatar		
Yahmaa	Saudi Arabia		





Accelerating penetration of Penthrox in global markets

Driving near term growth through commercial execution in existing markets, while planning for US market entry longer term

1. Increasing penetration in Australia

- 2. Leveraging market access in Europe
- 3. Growing in Rest of World markets
- 4. Progressing US market entry







Financial summary

\$million	FY22	FY23	Change \$m
Revenue ¹	21.9	32.3	10.4
Underlying EBIT	(14.7)	(18.3)	(3.6)
Underlying Adjustments (before tax) ²	(1.2)	10.3	11.5
Reported EBIT	(15.9)	(8.0)	7.9
NPAT	(12.4)	(5.6)	6.8
Operating apph flow	(10.9)	(17 1)	(6.2)
Operating cash flow	(10.8)	(17.1)	(6.3)
Cash	20.4	24.7	4.3

- Strong revenue growth with CAGR of 41.6% from FY21-FY23
- EBIT and operating cashflow in FY22 and FY23 reflects primary investment phase
- Primary investment phase complete, efficiencies to be delivered in future periods
- Closing cash balance in FY23 of \$24.7 million

9









Strong momentum toward positive operating cashflow in FY25

Incremental pricing and efficiency benefits of \$6 million expected in FY24, further step change in FY25

Pricing benefits

- Higher pricing in Australia
- Opportunity to reset commercial arrangements in other markets

Cost efficiencies

• European restructuring

Supply chain efficiency

Scale efficiencies





ASX:MVP

Medical Developments International

November 2023



Penthrox Inhaler

CRIPTION ONLY methoxyflu the second secon



Spac

Cham